Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Healthcare Sector Analysis

UpdatedAug 09, 2026
DataAggregated Company Financials
Companies34
  • 7D2.4%
  • 3M13.1%
  • 1Y31.5%
  • YTD12.3%

In the last week, the Healthcare industry is up 2.4%, with Roche Holding up 3.9%. This takes the industry's 12 month performance to a gain of 32%. Earnings are forecast to grow by 13% annually.

Sector Valuation and Performance

Has the Swiss Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 09 Aug 2026CHF 741.7bCHF 157.5bCHF 27.2b33.3x27.3x4.7x
Tue, 07 Jul 2026CHF 699.4bCHF 156.1bCHF 28.2b34.4x24.8x4.5x
Thu, 04 Jun 2026CHF 642.6bCHF 155.0bCHF 28.0b32.5x22.9x4.1x
Sat, 02 May 2026CHF 661.3bCHF 154.3bCHF 28.0b32.2x23.6x4.3x
Mon, 30 Mar 2026CHF 659.1bCHF 155.7bCHF 28.6b32.7x23x4.2x
Wed, 25 Feb 2026CHF 738.6bCHF 152.4bCHF 27.7b31.8x26.6x4.8x
Fri, 23 Jan 2026CHF 720.1bCHF 154.2bCHF 24.8b33.4x29x4.7x
Sun, 21 Dec 2025CHF 681.8bCHF 154.6bCHF 24.9b29.4x27.4x4.4x
Tue, 18 Nov 2025CHF 636.3bCHF 154.6bCHF 24.8b27.9x25.6x4.1x
Thu, 16 Oct 2025CHF 628.2bCHF 153.6bCHF 24.2b31.6x26x4.1x
Sat, 13 Sep 2025CHF 609.0bCHF 153.5bCHF 24.1b32.6x25.2x4x
Mon, 11 Aug 2025CHF 583.6bCHF 154.2bCHF 24.3b29.3x24x3.8x
Wed, 09 Jul 2025CHF 587.7bCHF 149.7bCHF 22.2b30.3x26.5x3.9x
Fri, 06 Jun 2025CHF 593.5bCHF 151.6bCHF 22.6b30.5x26.3x3.9x
Sun, 04 May 2025CHF 591.4bCHF 151.8bCHF 22.5b31x26.2x3.9x
Tue, 01 Apr 2025CHF 601.5bCHF 155.0bCHF 22.5b29.6x26.7x3.9x
Thu, 27 Feb 2025CHF 632.1bCHF 155.2bCHF 22.3b26.5x28.3x4.1x
Sat, 25 Jan 2025CHF 604.1bCHF 152.6bCHF 24.5b31.1x24.6x4x
Mon, 23 Dec 2024CHF 556.2bCHF 151.7bCHF 24.4b28.1x22.8x3.7x
Wed, 20 Nov 2024CHF 566.5bCHF 150.9bCHF 24.3b28.1x23.3x3.8x
Fri, 18 Oct 2024CHF 616.5bCHF 148.6bCHF 22.6b31x27.3x4.1x
Sun, 15 Sep 2024CHF 604.8bCHF 147.2bCHF 22.3b32.8x27.1x4.1x
Tue, 13 Aug 2024CHF 604.7bCHF 148.1bCHF 22.3b29.6x27.1x4.1x
Thu, 11 Jul 2024CHF 584.3bCHF 149.1bCHF 22.7b37.6x25.7x3.9x
Sat, 08 Jun 2024CHF 572.5bCHF 148.9bCHF 22.7b35.4x25.2x3.8x
Mon, 06 May 2024CHF 528.8bCHF 145.7bCHF 22.8b32.8x23.2x3.6x
Wed, 03 Apr 2024CHF 548.4bCHF 144.8bCHF 22.3b36.1x24.6x3.8x
Fri, 01 Mar 2024CHF 527.5bCHF 143.3bCHF 22.7b35.8x23.3x3.7x
Sun, 28 Jan 2024CHF 546.3bCHF 152.6bCHF 21.4b34x25.5x3.6x
Tue, 26 Dec 2023CHF 522.8bCHF 151.6bCHF 21.8b26.3x24x3.4x
Thu, 23 Nov 2023CHF 513.5bCHF 153.9bCHF 22.1b24.5x23.2x3.3x
Sat, 21 Oct 2023CHF 505.6bCHF 153.2bCHF 21.6b25.7x23.4x3.3x
Mon, 18 Sep 2023CHF 551.7bCHF 145.0bCHF 21.1b35.4x26.1x3.8x
Wed, 16 Aug 2023CHF 548.9bCHF 143.5bCHF 21.1b32.1x26x3.8x
Price to Earnings Ratio

26x


Total Market Cap: CHF 548.9bTotal Earnings: CHF 21.1bTotal Revenue: CHF 143.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Healthcare Sector Price to Earnings3Y Average 25.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 25.3x.
  • The 3-year average PS ratio of 4.0x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 8.8% per year over the last three years.
  • Revenues for these companies have grown 3.1% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare sector?

CH Market1.72%
Healthcare2.41%
Healthtech9.98%
Medical Equipment3.76%
Pharma2.38%
Life Sciences1.68%
Biotech1.04%
Healthcare Services-3.59%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 47.0x.
    • Analysts are expecting annual earnings growth of 19.3%, which is higher than its past year's earnings growth of 8.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 39% over the next 5 years.
  • This is better than its past earnings decline of 48% per year.
  • In contrast, the Healthtech industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 367.303.9%
+CHF 10.9b		49.1%PE23.7x
SDZ Sandoz GroupCHF 72.7810.7%
+CHF 3.0b		53.9%PE60.4x
GALD Galderma GroupCHF 181.353.2%
+CHF 1.3b		39.4%PE60.7x
ALC AlconCHF 57.343.5%
+CHF 955.9m		-17.0%PE42.3x
SOON Sonova HoldingCHF 235.607.1%
+CHF 926.7m		4.8%PE26.1x

Latest News

SDZ
CHF 72.78
Sandoz Group
7D
10.7%
1Y
53.9%
GALE
CHF 82.20
Galenica
7D
-4.4%
1Y
-2.5%
BANB
CHF 73.65
Bachem Holding
7D
-1.5%
1Y
9.8%
ROP
CHF 367.30
Roche Holding
7D
3.9%
1Y
49.1%
NOVN
CHF 125.98
Novartis
7D
-0.5%
1Y
33.9%
IDIA
CHF 6.01
Idorsia
7D
-1.8%
1Y
131.4%
STMN
CHF 102.90
Straumann Holding
7D
3.0%
1Y
1.9%
Narrative Update • Aug 03

STMN: Rich Multiples Will Likely Limit Upside As China Risks Persist

Analysts have nudged their Straumann Holding price expectations higher, with the internal fair value estimate moving from CHF 83.0 to CHF 85.0 as recent Street research highlights a series of raised price targets across both cautious and more optimistic coverage. Analyst Commentary Recent Street views on Straumann Holding show a wide spread in price targets, which gives you a useful snapshot of how divided sentiment remains on the stock.
GALD
CHF 181.35
Galderma Group
7D
3.2%
1Y
39.4%
Narrative Update • Jul 30

GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction

Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.
LONN
CHF 572.20
Lonza Group
7D
1.8%
1Y
5.1%
Narrative Update • Jul 24

LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside

Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.
SOON
CHF 235.60
Sonova Holding
7D
7.1%
1Y
4.8%
Narrative Update • Jul 22

SOON: Mixed Rating Shifts And Dividend Outlook May Steady P E Over Time

The analyst price target for Sonova Holding has been raised from CHF 216.51 to CHF 221.83, as analysts cite relative valuation versus peers and indications of a possible growth inflection in recent sector research. Analyst Commentary Recent research on Sonova Holding shows a mix of optimism about potential growth and ongoing caution around valuation and execution, giving you a more balanced view of how the stock is being framed by the market.
ALC
CHF 57.34
Alcon
7D
3.5%
1Y
-17.0%
Narrative Update • Jul 21

ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook

Analysts have trimmed their Alcon price target to CHF56.59 from CHF57.82, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E levels. What's in the News for Alcon Alcon and RxSight entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight’s postoperative light-adjustable technology with Alcon’s PCIOL optical designs to allow surgeons to fine-tune vision for cataract patients after surgery.
SFZN
CHF 79.65
Siegfried Holding
7D
5.1%
1Y
-8.2%
AEVS
CHF 12.80
Aevis Victoria
7D
-0.8%
1Y
-3.0%
MOLN
CHF 3.24
Molecular Partners
7D
-2.7%
1Y
10.2%
VBSN
CHF 126.00
IVF Hartmann Holding
7D
-1.2%
1Y
-9.4%
CURN
CHF 20.00
Curatis Holding
7D
-2.0%
1Y
68.1%